Latest news and press releases about Soligenix, Inc. (SNGX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions.
Price
| Price | $0.36 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.86 |
| EV / EBITDA | 0.36 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -181.02% |
| Return on Invested Capital | -151.39% |
| Return on Assets | -97.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CANF · CMND · ENSC · KZIA · OGEN · QLGN · SILO
Explore sector: Healthcare · Biotechnology
More sections of SNGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks